Blood sugar reducing compound, preparation method of blood sugar reducing compound, medicine composition including blood sugar reducing compound and application of medicine composition
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compounds and mixtures, applied in the field of preparation of hypoglycemic drugs
Inactive Publication Date: 2014-07-02
BEIJING LABSOLUTIONS PHARMA
View PDF16 Cites 9 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Moreover, when saxagliptin is used in combination with thiazolidinediones (TZDs), common adverse reactions include hypoglycemia
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0513] At room temperature, dissolve saxagliptin (4g, 12mmol) in 50ml DMF, add K 2 CO 3 (5g, 36mmol), (Boc) 2 O (5.2g, 24mmol), reacted for 18 hours, added 100ml of dichloromethane, washed four times with water, Na 2 SO 4 Drying and concentration gave 5.4g of the product N-tert-butoxycarbonyl-(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyl-1-adamantyl)-acetyl Base]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, the compound is C 23 h 33 N 3 o 4 , the calculated value of MS-ESI (m / z) is 415.25; the found value is 438.24 (100, MNa+).
[0514] At room temperature, N-tert-butoxycarbonyl-(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)-acetyl]-2 -Azabicyclo[3.1.0]hexane-3-carbonitrile (500mg, 1.2mmol) was dissolved in 20ml of dichloromethane, N-Boc-glycine (1053mg, 6.1mmol) was added, DIC (922mg, 7.2mmol) , DMA...
[0519] Prepared as described in Example 1 except that N-tert-butoxycarbonyl-L-alanine was used instead of N-tert-butoxycarbonyl-L-glycine. The resulting compound is C 21 h 30 N 4 o 3 , the calculated value of MS-ESI (m / z) is 386.23; the measured value is 387.13 (100, MH + ).
[0523] Prepared as described in Example 1 except that N-tert-butoxycarbonyl-D-alanine was used instead of N-tert-butoxycarbonyl-L-glycine. The resulting compound is C 21 h 30 N 4 o 3 , the calculated value of MS-ESI (m / z) is 386.23; the measured value is 387.11 (100, MH + ).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a blood sugar reducing compound, a preparation method of the blood sugar reducing compound, a medicine composition including the blood sugar reducing compound and an application of the medicine composition. The compound is a compound shown in a general formula (I) or a pharmaceutically acceptable salt, a solvate, a polymorphism body, an enantiomer or a racemic mixture thereof, the general formula is described in the specification, wherein R1, R2, R3 and R4 are independently H, optionally substituted alkyl, optionally substituted naphthenic base, optionally substituted alkoxy, optionally substituted aryl, optionally substituted aralkyl, or optionally substituted naphthenic base formed by R1 and R2, or optionally substituted heterocyclic radical formed by R2 and R3, or optionally substituted heterocyclic radical formed by R3 and R4. The compound is actively transported by a PepT1 transporter to be absorbed by the gastrointestinal tract, and decomposed in the intestinal tract and the liver to slowly generate saxagliptin, thus the blood concentration of the saxagliptin is increased, and the retention time of the saxagliptin in blood is prolonged. The blood sugar reducing treatment effect is favorably increased and the side reaction is favorably reduced due to stable blood concentration.
Description
technical field [0001] The present invention relates to a kind of hypoglycemic compound and a preparation method thereof, as well as a pharmaceutical composition containing the hypoglycemic compound and the use of the hypoglycemic compound in preparing hypoglycemic drugs. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by elevated blood sugar caused by defects in insulin secretion and (or) action. Diabetic patients with long-term poor blood sugar control may be accompanied by various organs, especially eye, heart, blood vessel, kidney, nerve damage or organ insufficiency or failure, resulting in disability or premature death. In recent years, with the development of social economy and the improvement of residents' living standards in various countries in the world, the incidence and prevalence of diabetes have increased year by year, becoming a major social problem that threatens people's health, causing governments, health departments an...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more